DS
HARP

David Shaw’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

David Shaw’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,873
Closed -$36K – 5672
2022
Q2 		$36K Buy
+1,873
New +$48.5K ﹤0.01% 4900

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

David Shaw's HARP Position: Q3 2022 in Review

David Shaw sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2022, closing a stake of 1,873 shares — an estimated $36K sold.

David Shaw first reported a position in HARP in Q2 2022 and held it in 1 quarter. The position peaked at $36K in Q2 2022. 52 funds tracked by Wall St. Rank hold HARP as of Q3 2022.

  • David Shaw reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 1,873 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $36K.
  • David Shaw first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • David Shaw's Harpoon Therapeutics, Inc. Common Stock position peaked at $36K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.